Overview

Pola-ZR2P in Previously Untreated DLBCL

Status:
RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.
Phase:
PHASE2
Details
Lead Sponsor:
Navy General Hospital, Beijing
Treatments:
Lenalidomide
Neoadjuvant Therapy
polatuzumab vedotin
Prednisone
Rituximab
zanubrutinib